Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2010. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the allocation of share awards to Non-Executive Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly a regulatory disclosure of director share transactions and does not contain financial performance data.
Material Changes
On December 31, 2009, Non-Executive Directors were provisionally allocated awards over Ordinary shares and American Depository Shares (ADSs) through the annual reinvestment of dividends paid throughout 2009. The Company and Directors were informed of these allocations on January 4, 2010.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- The filing details specific share allocations for Non-Executive Directors resulting from 2009 dividend reinvestment.
- Allocations were made in both Ordinary Shares (average price £13.25) and ADSs (average price $42.40).
- Directors receiving allocations include Sir Christopher Gent, Prof Sir Roy Anderson, Dr Stephanie Burns, Mr Lawrence Culp, Sir Crispin Davis, Sir Deryck Maughan, Mr James Murdoch, Dr Daniel Podolsky, Mr Tom de Swaan, and Sir Robert Wilson.
- This document does not report on the company's operational or financial performance for the period.